The results of the present study demonstrated that for patients with BRAF V600E-mutated advanced CRC, chemotherapy alone did not differ significantly in OS and PFS compared with chemotherapy + bevacizumab for advanced first-line therapy. The gene discussed is BRAF; the disease is colorectal carcinoma.